ArticleJournal of cellular and molecular medicine2025
Ephedrine Attenuates LPS-Induced Acute Lung Injury in Mice by Inhibiting OTUB1 and Promoting K48 Ubiquitination of HIF1α.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Acute lung injury (ALI) is a severe inflammatory lung disorder that requires effective therapeutic strategies. Ephedrine (EPH) is the main active component found in medicinal plants of the Ephedra genus and is commonly used to modulate inflammatory responses in various diseases. Hypoxia-inducible factor 1-alpha (HIF1α) is a subunit of hypoxia-inducible factor 1 (HIF1), which plays a critical regulatory role in cellular responses under hypoxic conditions. Moreover, the degradation pathway of HIF1α is regulated by the deubiquitinase Ovarian Tumour Domain-containing Ubiquitin Aldehyde Binding Protein 1 (OTUB1). The aim of this study is to investigate the therapeutic effects of EPH on ALI and its potential therapeutic mechanism. We utilised a lipopolysaccharide (LPS)-induced ALI mouse model and employed various methods for evaluation. Ultimately, our research findings demonstrate that EPH exhibits anti-ALI effects, with the involvement of HIF1α and OTUB1 in the pharmacological actions of EPH. In conclusion, our study results demonstrate that EPH exhibits anti-ALI effects and exerts its protective effects through modulation of the OTUB1 and HIF1α pathways. Our research findings not only lay the foundation for expanding the medicinal applications of EPH but also provide direction for seeking improved treatment strategies for ALI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.